Saniona completes SAN2465 tox, CMC studies, targets IND filing by end-October 2026
Bitget2026/09/24 06:03- Saniona completed toxicology and CMC work for SAN2465, clearing the package needed to support an IND filing.
- IND submission to the FDA is targeted by end-October 2026, setting up first-in-human dosing plans.
- Planned Phase 1 trial targets safety, tolerability, pharmacokinetics in healthy volunteers, with biomarker readouts to inform dose selection.
- SAN2465 targets GABA-A α5 receptors for major depressive disorder, aiming for ketamine-like rapid onset with an oral profile.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ethereum’s $2,540 Retest Becomes Key Test for the Rally
Canton Network breaks 2 month range! – CC’s run to $0.15 depends on THIS zone
Analysis: Wall Street Is Not Yet Ready to Short AI in Large Numbers
Overseas capital is aggressively buying US stocks! Net inflows reached $942 billions over the past 12 months, marking a record since 1985.
According to data from the US Department of the Treasury, in the 12 months ending July this year, overseas investors made net purchases of US stocks totaling $942 billion, marking the highest rolling 12-month total since records began in 1985. The net purchases in the second quarter alone reached $426 billion, setting a new single-quarter record. Meanwhile, overseas demand for US Treasuries has noticeably cooled, with purchase volumes falling significantly. As a result, the US is facing higher costs in government debt financing.
Crypto prices
More
